Overview

Iressa Expanded Access Program (EAP)

Status:
Completed

Trial end date:
2003-10-01

Target enrollment:

Participant gender:

Summary

A program for patients with non small cell lung cancer who may benefit from Iressa, but cannot enter another clinical trial due to them not being eligible, or for whom no trials are available.

Phase:

Phase 3

Details

Lead Sponsor:

AstraZeneca

Treatments:

Gefitinib